171 related articles for article (PubMed ID: 19736245)
1. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.
Jong NN; Nakanishi T; Liu JJ; Tamai I; McKeage MJ
J Pharmacol Exp Ther; 2011 Aug; 338(2):537-47. PubMed ID: 21606177
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of fructose 1,6 bisphosphatase in monitoring renal proximal tubular injury.
Pfaller W; Thorwartl U; Nevinny-Stickel M; Krall M; Schober M; Joannidis M; Hobisch A
Kidney Int Suppl; 1994 Nov; 47():S68-75. PubMed ID: 7532742
[TBL] [Abstract][Full Text] [Related]
4. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice.
Kano T; Kato Y; Ito K; Ogihara T; Kubo Y; Tsuji A
Drug Metab Dispos; 2009 May; 37(5):1009-16. PubMed ID: 19220985
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
6. Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans.
Morand R; Todesco L; Donzelli M; Fischer-Barnicol D; Mullen PJ; Krähenbühl S
Ther Drug Monit; 2012 Aug; 34(4):406-14. PubMed ID: 22743351
[TBL] [Abstract][Full Text] [Related]
7. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1).
Glube N; Closs E; Langguth P
Mol Pharm; 2007; 4(1):160-8. PubMed ID: 17274673
[TBL] [Abstract][Full Text] [Related]
8. Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2.
Todesco L; Bodmer M; Vonwil K; Häussinger D; Krähenbühl S
Chem Biol Interact; 2009 Aug; 180(3):472-7. PubMed ID: 19539806
[TBL] [Abstract][Full Text] [Related]
9. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
10. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
Yonezawa A; Masuda S; Nishihara K; Yano I; Katsura T; Inui K
Biochem Pharmacol; 2005 Dec; 70(12):1823-31. PubMed ID: 16242669
[TBL] [Abstract][Full Text] [Related]
11. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
Wu X; Huang W; Prasad PD; Seth P; Rajan DP; Leibach FH; Chen J; Conway SJ; Ganapathy V
J Pharmacol Exp Ther; 1999 Sep; 290(3):1482-92. PubMed ID: 10454528
[TBL] [Abstract][Full Text] [Related]
12. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
13. Functional expression of the organic cation/carnitine transporter 2 in rat astrocytes.
Inazu M; Takeda H; Maehara K; Miyashita K; Tomoda A; Matsumiya T
J Neurochem; 2006 Apr; 97(2):424-34. PubMed ID: 16539668
[TBL] [Abstract][Full Text] [Related]
14. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
15. PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell surface expression.
Watanabe C; Kato Y; Sugiura T; Kubo Y; Wakayama T; Iseki S; Tsuji A
Drug Metab Dispos; 2006 Nov; 34(11):1927-34. PubMed ID: 16896066
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Mancinelli A; D'Iddio S; Bisonni R; Graziano F; Lippe P; Calvani M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):19-26. PubMed ID: 16988826
[TBL] [Abstract][Full Text] [Related]
17. Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium.
Garrett Q; Xu S; Simmons PA; Vehige J; Flanagan JL; Willcox MD
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4844-9. PubMed ID: 18641280
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats.
Uehara T; Watanabe H; Itoh F; Inoue S; Koshida H; Nakamura M; Yamate J; Maruyama T
Arch Toxicol; 2005 Aug; 79(8):451-60. PubMed ID: 15856183
[TBL] [Abstract][Full Text] [Related]
19. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse.
Kato Y; Sugiura M; Sugiura T; Wakayama T; Kubo Y; Kobayashi D; Sai Y; Tamai I; Iseki S; Tsuji A
Mol Pharmacol; 2006 Sep; 70(3):829-37. PubMed ID: 16754783
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
